Using New Oral Anticoagulants in Patients Undergoing Major Orthopedic Surgery

被引：0
|
作者：
Anne R. Bass
机构：
[1] Weill Cornell Medical College,Hospital for Special Surgery
来源：
Current Rheumatology Reports | 2015年 / 17卷
关键词：
Rivaroxaban; Apixaban; Edoxaban; Dabigatran; Total knee replacement; Total hip replacement; Orthopedic surgery; Venous thromboembolism; Anticoagulation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Four new oral anticoagulants (NOAC), apixaban, rivaroxaban, edoxaban, and dabigatran, are now available in the USA; however, only apixaban and rivaroxaban are FDA approved for the prevention of venous thromboembolism following orthopedic surgery. Apixaban, rivaroxaban, and edoxaban’s anticoagulant activity can be measured using a chromogenic anti-factor Xa assay but there is no widely available means of measuring dabigatran blood levels. None of the NOAC has an antidote. Dabigatran is 80 % renally excreted, and patients with atrial fibrillation taking dabigatran for stroke prevention should stop the drug 4–5 days prior to major orthopedic surgery. Apixaban, rivaroxaban, and edoxaban should be held for 48 h preoperatively in this setting.
引用
收藏
相关论文
共 50 条
  • [1] Using New Oral Anticoagulants in Patients Undergoing Major Orthopedic Surgery
    Bass, Anne R.
    [J]. CURRENT RHEUMATOLOGY REPORTS, 2015, 17 (04)
  • [2] New anticoagulants and regional anaesthesia in patients undergoing orthopedic surgery
    Tripkovic, Branko
    Sakic, Simun
    [J]. PERIODICUM BIOLOGORUM, 2011, 113 (02) : 269 - 273
  • [3] New oral anticoagulants in orthopedic surgery: A retrospective study
    Boselli, Emmanuel
    Rahali, Najia
    Zadam, Abbes
    Allaouchiche, Bernard
    [J]. BRITISH JOURNAL OF ANAESTHESIA, 2012, 108 : 372 - 373
  • [4] The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery
    Rachidi, Saleh
    Aldin, Ehab Saad
    Greenberg, Charles
    Sachs, Barton
    Streiff, Michael
    Zeidan, Amer M.
    [J]. EXPERT REVIEW OF HEMATOLOGY, 2013, 6 (06) : 677 - 695
  • [5] Prevention of venous thromboembolism after major orthopedic surgery: indirect comparison of three new oral anticoagulants
    Maratea, D.
    Fadda, V.
    Trippoli, S.
    Messori, A.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 (09) : 1868 - 1870
  • [6] Rivaroxaban for Thromboprophylaxis in Patients Undergoing Major Orthopedic Surgery
    Melillo, Stephanie N.
    Scanlon, James V.
    Exter, Benjamin P.
    Steinberg, Michael
    Jarvis, Courtney I.
    [J]. ANNALS OF PHARMACOTHERAPY, 2010, 44 (06) : 1061 - 1071
  • [7] Novel Oral Anticoagulants in Patients Undergoing Cranial Surgery
    Croci, Davide Marco
    Kamenova, Maria
    Guzman, Raphael
    Mariani, Luigi
    Soleman, Jehuda
    [J]. WORLD NEUROSURGERY, 2017, 105 : 841 - 848
  • [8] Direct Oral Anticoagulants in Patients Undergoing Spine Surgery
    Croci, Davide Marco
    Dalolio, Martina
    Guzman, Raphael
    Mariani, Luigi
    Schaeren, Stefan
    Kamenova, Maria
    Soleman, Jehuda
    [J]. WORLD NEUROSURGERY, 2019, 125 : E1034 - E1041
  • [9] Assessing the Safety Profiles of New Anticoagulants for Major Orthopedic Surgery Thromboprophylaxis
    Hull, Russell D.
    Yusen, Roger D.
    Bergqvist, David
    [J]. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2009, 15 (04) : 377 - 388
  • [10] Venous Thromboembolism in Korean Patients Undergoing Major Orthopedic Surgery
    Cha, S.
    Yoo, S.
    Lee, S.
    Kim, C.
    Park, J.
    Jung, T.
    Kim, S.
    Choi, H.
    Jung, C.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
12345